Literature DB >> 14736434

Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease.

Daniel R Kaiser1, Kevin Billups, Carol Mason, Rebecca Wetterling, Jennifer L Lundberg, Alan J Bank.   

Abstract

OBJECTIVES: The goal of this study was to determine whether patients with vascular erectile dysfunction (ED) and no other clinical cardiovascular disease have structural and functional abnormalities of other vascular beds.
BACKGROUND: In many ED patients, vascular disease is the major underlying cause. It may be that ED is an early marker of atherosclerosis in patients without clinical cardiovascular disease.
METHOD: We assessed systemic vascular structure and function in 30 patients with ED and 27 age-matched normal control (NL) subjects. We measured vascular parameters, including: 1) carotid and brachial artery diameters, intima-media thickness, compliance, and distensibility; 2) aortic pulse wave velocity; 3) coronary calcification; and 4) brachial artery endothelium-dependent and -independent vasodilation.
RESULTS: There were no significant differences in baseline demographics, coronary artery risk score, or lipid values between the two groups. Most structural and functional vascular parameters were similar in the ED and NL groups. Brachial artery flow-mediated vasodilation (FMD) (1.3 vs. 2.4%, p = 0.014) and vasodilation to nitroglycerin (NTG) (13.0 vs. 17.8%, p < 0.05) were significantly reduced in ED patients, compared with NL subjects. In addition, there was a significant correlation between FMD and vasodilation to NTG in ED patients (r = 0.59, p < 0.05) but not in NL subjects.
CONCLUSIONS: Patients with ED but no clinical cardiovascular disease have a peripheral vascular defect in endothelium-dependent and -independent vasodilation that occurs before the development of other overt functional or structural systemic vascular disease and is independent of other traditional cardiovascular risk factors.

Entities:  

Mesh:

Year:  2004        PMID: 14736434     DOI: 10.1016/j.jacc.2003.07.042

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  49 in total

1.  Significant improvement of erectile function after Roux-en-Y gastric bypass surgery in obese Chinese men with erectile dysfunction.

Authors:  Li Kun; Zhang Pin; Di Jianzhong; Han Xiaodong; Yu Haoyong; Bao Yuqian; Zhang Hongwei
Journal:  Obes Surg       Date:  2015-05       Impact factor: 4.129

Review 2.  Should patients with erectile dysfunction be evaluated for cardiovascular disease?

Authors:  Kenneth A Ewane; Hao-Cheng Lin; Run Wang
Journal:  Asian J Androl       Date:  2011-11-28       Impact factor: 3.285

3.  Serum Arginase II level can be a novel indicator for erectile dysfunction in patients with vasculogenic erectile dysfunction: a comparative study.

Authors:  Abdel Shakour Abdel Hafez Abdel Wahed; Mohamed Abdel Mawgood Amer; Nagah Mohamed Abou Mohamed; Mohamed Ismael Mobasher; Hassan Mamdouh; Sameh Fayek GamalEl Din; Mohammed Said ElSheemy
Journal:  Int Urol Nephrol       Date:  2018-06-28       Impact factor: 2.370

4.  Small-vessel lower extremity arterial disease and erectile dysfunction: The Rancho Bernardo study.

Authors:  Shua J Chai; Elizabeth Barrett-Connor; Anthony Gamst
Journal:  Atherosclerosis       Date:  2008-08-07       Impact factor: 5.162

5.  Microvascular endothelial dysfunction predicts the development of erectile dysfunction in men with coronary atherosclerosis without critical stenoses.

Authors:  Martin Reriani; Andreas J Flammer; Jing Li; Megha Prasad; Charanjit Rihal; Abhiram Prasad; Ryan Lennon; Lilach O Lerman; Amir Lerman
Journal:  Coron Artery Dis       Date:  2014-11       Impact factor: 1.439

6.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

7.  Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials.

Authors:  V Fonseca; A Seftel; J Denne; P Fredlund
Journal:  Diabetologia       Date:  2004-11-25       Impact factor: 10.122

8.  Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil.

Authors:  O Özdabakoğlu; S Güllülü; S Sağ; T Şentürk; H Kiliçarslan; A Tütüncü; M Keçebaş; I Baran; A Aydinlar
Journal:  Int J Impot Res       Date:  2016-12-08       Impact factor: 2.896

9.  Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed men.

Authors:  B M Hoffman; A Sherwood; P J Smith; M A Babyak; P M Doraiswamy; A Hinderliter; J A Blumenthal
Journal:  Int J Impot Res       Date:  2009-09-24       Impact factor: 2.896

Review 10.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.